| Literature DB >> 35334615 |
Bogdan Huzum1,2, Alexandrina Stefania Curpan3, Bogdan Puha1, Dragomir Nicolae Serban2, Bogdan Veliceasa1, Riana Maria Necoara4, Ovidiu Alexa1, Ionela Lacramioara Serban2.
Abstract
The general opinion in the literature is that these topics remain clearly understudied and underrated, with many unknown aspects and with controversial results in the respective areas of research. Based on the previous experience of our groups regarding such matters investigated separately, here we attempt a short overview upon their links. Thus, we summarize here the current state of knowledge regarding the connections between oxidative stress and: (a) orthopedic conditions; (b) COVID-19. We also present the reciprocal interferences among them. Oxidative stress is, of course, an interesting and continuously growing area, but what exactly is the impact of COVID-19 in orthopedic patients? In the current paper we also approached some theories on how oxidative stress, metabolism involvement, and even antibiotic resistance might be influenced by either orthopedic conditions or COVID-19. These manifestations could be relevant and of great interest in the context of this current global health threat; therefore, we summarize the current knowledge and/or the lack of sufficient evidence to support the interactions between these conditions.Entities:
Keywords: COVID-19; antibacterial resistance; orthopedic; orthopedic surgery; osteoarthritis; osteoporosis; oxidative stress
Mesh:
Year: 2022 PMID: 35334615 PMCID: PMC8951198 DOI: 10.3390/medicina58030439
Source DB: PubMed Journal: Medicina (Kaunas) ISSN: 1010-660X Impact factor: 2.430
Orthopedic conditions and the risks associated with COVID-19 infection.
| Risks | RA | Osteoarthritis | Osteoporosis and Bone Fractures | Diabetes and MetS | Medication for Orthopedic Conditions |
|---|---|---|---|---|---|
|
| ↑ [ | No apparent association [ | N.D. | ↑ [ | Systemic therapies no increasing risk [ |
|
| ↑ [ | N.D. | ↑ risk with a history of hip [ | ↑ [ | N.D. |
|
| ↑ [ | N.D. | ↑ risk for hip fracture patients [ | N.D. | |
|
| ↑ [ | N.D. | ↑ in patients with VFs [ | ↑ [ | |
|
| ↑ [ | N.D. | ↑ risk with a history of hip [ | ↑ [ | At-home glucose-lowering drugs showed no sign. Association with mortality and adverse outcomes [ |
|
| ↑ [ | N.D. | ↑ [ | ↑ [ | N.D. |
|
| ↑ risk of venous thromboembolism and sepsis [ | N.D. | ↑ risk of vertebral fractures among patients with severe SARS-CoV-2 [ | Diabetes in pediatric population [ | N.D. |
|
| Inflammatory reactive arthritis [ | Type 1 Diabetes [ | N.D. |
N.D.—not determined, GC—glucocorticoids, RA—rheumatoid arthritis, TNFis—tumor necrosis factor inhibitors, VFs—venous fibrillation, NSAIDs—Non-steroidal anti-inflammatory drugs.